Under the proposed plans outlined by NICE, to be eligible to receive the drug first, patients would need to have BMI over 40 and at least three specified weight-related health problems: hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease
Check your insurers website for their preferred forms and eligibility criteria
Summary: Ozempic (semaglutide) is not officially recognised as causing anxiety based on current UK regulatory data and clinical trials, though occasional patient reports exist without established causation
Adequate protein intake (at least 0.8 to 1.0 grams per pound of body weight), micronutrient supplementation, and gradual dose titration can help minimize this effect
Both Novo Nordisk and Eli Lilly have taken steps to try to lower costs and ease access, such as creating online platforms and offering single-dose vials instead of injector pens
Section 503A Compounding